Table 3.
Identification of prognostic survival markers in MBGrp3 and MBGrp4 cohorts
| n |
Univariate (n=175) |
Cross-validated multivariate (n=133) |
|||
|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | ||
| High-risk methylation group vs low-risk methylation group | 175 | 3·73 (1·94–7·18) | <0·0001 | 3·21 (1·59–6·51) | 0·0012 |
| MYC amplification vs no amplification | 173 | 2·94 (1·06–8·13) | 0·038 | 18·4 (5·01–67·7) | <0·0001 |
| Loss of chromosome 13 vs no loss | 158 | 0·10 (0·01–0·74) | 0·024 | 0·06 (0·01–0·49) | 0·0090 |
| MBGrp3vs MBGrp4 | 175 | 2·04 (1·23–3·40) | 0·006 | .. | .. |
| M+ vs M– disease | 171 | 1·77 (1·03–3·05) | 0·039 | .. | .. |
| i17q vs no i17q | 158 | 1·71 (0·99–2·95) | 0·056 | .. | .. |
| Male vs female | 175 | 1·56 (0·86–2·84) | 0·144 | .. | .. |
| MYCN amplification vs no amplification | 173 | 0·72 (0·23–2·29) | 0·576 | .. | .. |
| LCA pathology vs non-LCA pathology | 157 | 1·08 (0·49–2·39) | 0·848 | .. | .. |
| R+ vs R– disease | 171 | 1·22 (0·72–2·09) | 0·464 | .. | .. |
Identification of prognostic survival markers in combined childhood non-MBSHH and non-MBWNT survival cohort (aged 3·0–16·0 years, receiving craniospinal irradiation, with survival information). p values from Cox proportional hazards analyses are shown. The characteristics of covariates selected in cross-validated multivariate models are also shown. The high-risk methylomic group comprised samples from both MBGrp3 and MBGrp4, defined by the shared MBGrp3/4 metagene V1. HR=hazard ratio. MB=medulloblastoma. Grp3=group 3. Grp4=group 4. M+=metastatic disease. M–=non-metastatic disease. i17q=isochromosome 17q. LCA=large-cell anaplastic. R+=residual disease (subtotal surgical resection). R–=no residual disease (gross total resection).